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Abstract
Background: The ATLAS programme aims to promote and implement HIV self-testing (HIVST) in three West African
countries: Côte d’Ivoire, Mali, and Senegal. During 2019–2021, in close collaboration with the national AIDS implementing
partners and communities, ATLAS plans to distribute 500,000 HIVST kits through eight delivery channels, combining
facility-based, community-based strategies, primary and secondary distribution of HIVST.
Considering the characteristics of West African HIV epidemics, the targets of the ATLAS programme are hard-to-reach
populations: key populations (female sex workers, men who have sex with men, and drug users), their clients or sexual
partners, partners of people living with HIV and patients diagnosed with sexually transmitted infections and their partners.
The ATLAS programme includes research support implementation to generate evidence for HIVST scale-up in West Africa.
The main objective is to describe, analyse and understand the social, health, epidemiological effects and cost-
effectiveness of HIVST introduction in Côte d’Ivoire, Mali and Senegal to improve the overall HIV testing
strategy (accessibility, efficacy, ethics).
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Methods: ATLAS research is organised into five multidisciplinary workpackages (WPs):
– Key Populations WP: qualitative surveys (individual in-depth interviews, focus group discussions) conducted
with key actors, key populations, and HIVST users.
– Index testing WP: ethnographic observation of three HIV care services introducing HIVST for partner testing.
– Coupons survey WP: an anonymous telephone survey of HIVST users.
– Cost study WP: incremental economic cost analysis of each delivery model using a top-down costing with
programmatic data, complemented by a bottom-up costing of a representative sample of HIVST
distribution sites, and a time-motion study for health professionals providing HIVST.
– Modelling WP: Adaptation, parameterisation and calibration of a dynamic compartmental model that
considers the varied populations targeted by the ATLAS programme and the different testing modalities
and strategies.
Discussion: ATLAS is the first comprehensive study on HIV self-testing in West Africa. The ATLAS programme
focuses particularly on the secondary distribution of HIVST. This protocol was approved by three national ethic
committees and the WHO’s Ethical Research Committee.
Keywords: HIV/AIDS, HIV self-testing, West Africa, Senegal, Côte d’Ivoire, Mali
Background
In West Africa, HIV prevalence ranges from 0.3 to 3.4%
in the general adult population [1]. These epidemics are
usually classified as “generalised” (above 1%). Despite
this, key populations (female sex workers (FSW), men
who have sex with men (MSM), people who use inject-
able drugs (PWuID)) and vulnerable populations (de-
pending on the country: men in uniform, mobile
workers, clients of FSW, etc.) are important to local HIV
transmission dynamics [2].
In 2019, only 68% of people living with HIV (PLHIV)
in West Africa were aware of their HIV status, 58% were
on antiretroviral (ARV) therapy and 45% had an un-
detectable viral load [1], all of which are far from the
levels required to achieve epidemic control. The first
step of the HIV care cascade, HIV testing, is also the
most important gap to fill to attain the 90–90-90
UNAIDS targets [3]. The WHO/UNAIDS meeting held
in Dakar in November 2017 highlighted the urgent need
to accelerate progress on HIV testing in West Africa and
to adopt innovative and tailored testing approaches to
reach those who have not yet been tested [4].
Over the past decade, considering the concentrated as-
pect of local epidemics, national AIDS programmes have
increasingly developed actions specifically targeting key
populations who are particularly vulnerable to HIV ac-
quisition and transmission. Community-based activities
have thus improved access to HIV testing among those
reached by peer educators, FSW and MSM in particular,
while activities targeting PWuID were less common.
Despite these initiatives, key populations remain diffi-
cult to reach, particularly hidden MSM and occasional
FSW [5]. While HIV stigma and distance from services
are common barriers to HIV testing for the entire
population in West Africa, key populations exhibit lower
HIV testing rates and face specific additional barriers due
to socially stigmatised and even illegal practices [6–9].
Epidemic dynamics are complex and understanding
heterogeneity in the risk of HIV acquisition and trans-
mission is crucial for maximising the impact of the HIV
response [10]. Approximately 30% of new infections are
estimated to occur among people who engage in low-
risk behaviours but have partners with high-risk behav-
iours, such as unprotected sex with a partner whose HIV
status is unknown or multiple unprotected sexual part-
nerships [11]. According to two modelling studies, 44%
of new infections arising in Côte d’Ivoire from 2005 to
2015 occurred in partnerships between clients and their
non-FSW female partners [12], while over the same
period, 38% of new HIV infections occurring in Dakar
and Senegal were within non-commercial partnerships
between FSW and clients [13].
HIV self-testing: an innovative and powerful tool for
testing with remaining research gaps
HIV self-testing (HIVST) is a process in which the user
takes a sample (oral fluid or blood), performs the HIV
test, and then interprets the result alone, often in a pri-
vate setting (WHO 2016).
Several studies have shown that, for many users, HIVS
T promotes discretion and autonomy, HIV test uptake
by first-time testers and is associated with increased test-
ing frequency [14–17]. HIVST has high acceptability,
particularly among key populations and those who do
not test regularly [18–21].
Distribution strategies for HIVST can be based on a
primary distribution where the HIVST kit is given dir-
ectly to the person who will perform the test [20, 22] or
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on a secondary distribution where the HIVST is given to a
relay person who will redistribute it to one or many of
his/her contacts. Secondary distribution makes it possible
to reach hidden key populations, such as clients of FSW
[23, 24], partners of MSM [25], or index partners of preg-
nant women [26–28] who are not routinely tested. The
ability of primary contacts to distribute HIVST kits to
their contacts is not guaranteed, as secondary distribution
may be limited due to specific barriers and may be accom-
panied by social consequences, such as acts of violence
against FSW by their clients [22, 23].
In sub-Saharan Africa, partners of PLHIV are among
the priority target populations for testing because they
are at particular risk for HIV infection. Indeed, some
studies estimate that up to two-thirds of new infections
occur in heterosexual couples [29]. In many couples, one
or both partners do not know their HIV status [30]. Dif-
ficulties in disclosing one’s status due to HIV-related
stigma, leading to low rates of partner sharing, have
been reported [31–35]. HIVST is a complementary tool
to other HIV testing support activities for partners of
PLHIV. HIVST can be a way to initiate a dialogue on
HIV between partners when a partner is not informed.
This disclosure can have consequences for the couple
(separation, violence, dialogue, support) [36, 37] and also
for the partner’s willingness to undergo HIVST. In all
these issues, the gender dimension is an important elem-
ent. Indeed, men and women do not manage disclosure
of HIV status similarly, nor do they manage the relation-
ship to HIV test results in the same way [38].
Sexually transmitted infections (STI) counselling pro-
vides an opportunity for HIV testing for both patients
and their partners [39]. People infected with sexually
transmitted infections (STIs) are also at higher risk for
HIV infection [40]. It has been shown that the use of
STI counselling among individuals who thought they
were at risk of HIV infection was higher than that
among those who did not think they were at risk. Fur-
thermore, although HIV testing at STI consultations is
recommended, the percentage of testing initiated in this
context remains low. A recent study in Côte d’Ivoire
found that only 28% of patients who had an STI medical
consultation were offered HIV testing [41].
Only a few pilot experiments in HIV self-testing have
been implemented in West Africa. There is a strong de-
mand for the implementation of new innovative preven-
tion and testing tools, such as HIVST, in the region [42,
43]. One study in Senegal showed that HIVST repre-
sents an approach that reached first-time testers and
those who had not been tested recently [44]. The intro-
duction of HIV self-testing in West Africa may help to
remove some of the barriers faced by key and vulnerable
populations and improve their access to HIV testing, as
observed in other parts of Africa [25, 45].
The ATLAS programme
Following the WHO recommendations and the experi-
ence gained in East and Southern Africa through the
STAR programme [46], Unitaid and other countries
wished to promote and implement HIV self-testing in
West Africa through funding the ATLAS programme in
Côte d’Ivoire, Mali and Senegal. During 2019–2021,
ATLAS plans to dispense more than 500,000 HIV self-
test kits. Only oral HIVST OraQuick HIV Self-Test®
(OraSure Technologies, LLC Bethlehem) will be used as
it is pre-qualified by WHO and has been validated by
the three countries of intervention.
In each country, the provision of HIVST is comple-
mentary and integrated into existing HIV testing strat-
egies and will be performed by field workers already
engaged in testing activities financed by the Global Fund
or PEPFAR. Different delivery channels and target popu-
lations for each country have been developed in collab-
oration with the countries’ stakeholders (national AIDS
programmes/councils, international institutions, includ-
ing WHO, international and national NGOs involved in
local HIV programmes, civil society, communities).
Eight delivery channels have been selected for the
ATLAS programme after discussion with various stake-
holders (Fig. 1). Five delivery channels adopt a facility-
based strategy (delivery of HIVST in a health facility),
and three delivery channels adopt a community-based
strategy through field activities.
Due to the West African epidemiological and social
context, the ATLAS programme plans to promote sec-
ondary distribution in each of the eight delivery channels
to reach beyond those reached through primary distribu-
tion by health care workers and peer educators.
Research needs
Implementation of HIVST in West Africa raises specific
questions related to the cultural, social, economic, and
epidemiological contexts of this region. Furthermore,
questions remain regarding specific delivery channels
and secondary distribution in particular.
The social dimensions of HIV testing in general, and
of HIVST in particular, play an important role and im-
pact the acceptability and uptake of HIVST in different
populations and contexts [47]. Regardless of the percep-
tions and attitudes of populations and health workers,
the quality and organisation of health services is an es-
sential factor that can promote or limit access to testing.
More generally, documentation of the factors facilitating
or limiting HIVST is a way to support the implementa-
tion of tailored activities.
Because of the large proportion of HIVST secondary
distribution, routinely collected programmatic data will
be insufficient to describe the sociodemographic profiles
of HIVST users, as well as their trajectories of care
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following a reactive HIVST. In addition to its health im-
pact, HIVST could have other social consequences,
harmful or beneficial, not foreseen by the health system.
For example, some people could be coerced by their
partner to be tested, and a reactive result could be a
source of violence. Despite challenges, documenting the
profile of HIVST users and the social and health conse-
quences of HIVST is essential.
With HIVST being integrated with other conventional
HIV testing strategies, it is important to evaluate the
routine incremental costs of adding HIVST to existing
services and its associated epidemiological impacts for
each delivery channel. These data are essential for na-
tional programmes and technical and financial partners
to prepare for scaling up by comparing different possible
scenarios of distribution channels, population and esti-
mating cost-effectiveness and budgetary impacts.
Scientific objectives
The primary objective of the research component em-
bedded in the ATLAS programme is to describe, ana-
lyse and understand the social, health, epidemiological
and economic effects of the introduction of HIV self-
testing in Côte d’Ivoire, Mali and Senegal to improve
the availability of testing (accessibility, efficacy and
ethics).
This primary objective can be subdivided into six sec-
ondary objectives:
➔ Identify the social, cultural and organisational
factors facilitating and limiting the primary and
secondary distribution of HIV self-tests and their use/
appropriation by the different actors concerned
(programme or project manager and NGO representa-
tive, delivery agents, primary contacts, secondary
contacts).
➔ Establish the socio-behavioural profile and HIV test-
ing history of HIV self-test users and their care history
in the event of a reactive self-test.
➔ Analyse the positive and negative social and health
consequences of the introduction of HIV self-testing
for individuals, communities and the health system.
➔ Estimate the incremental costs of dispensing HIV
self-tests per delivery channel.
➔ Model the epidemiological impacts of the ATLAS
programme and different scaling scenarios on epidemic
dynamics.
➔ Estimate the medium- and long-term cost-
effectiveness and budgetary impact of different strat-
egies for scaling-up.
Methods and analysis
This protocol is based on version 2.1 of the ATLAS re-
search protocol. In case of future updates, the latest ver-
sion of the protocol will be available on https://atlas.
solthis.org/recherche/.
The ATLAS research component brings together
multidisciplinary researchers from different institutions
Fig. 1 ATLAS delivery channels
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in partnership with the different operational teams of
the programme.
Research activities embedded within the ATLAS
programme are organised into 5 work packages: (i) a
qualitative survey on HIVST focused on key populations
and based on qualitative individual and group interviews
with key implementers, members of key population
communities and HIVST users; (ii) an ethnography on
the integration of HIVST for screening PLHIV’s partners
in three HIV care clinics; (iii) an anonymous telephone
survey of HIVST users recruited through an invitation
on HIVST kits to call a toll-free number; (iv) an eco-
nomic survey of HIVST incremental costs with cost col-
lections from a sample of HIVST dispensing sites and a
time and motion study; (v) an epidemiological modelling
(dynamic compartmental model) of the three countries
and of the health and economic impacts of different
scaling scenarios.
The five work packages (WPs) with the six secondary
objectives (SO) and specific objectives are summarised
in Tables 1 and 2.
Key populations WP
The specific objectives of this WP are to identify factors
that promote and limit the integration of HIV self-
testing into the health care system and the primary and
secondary distribution of HIV self-tests in key popula-
tions (FSW, MSM and PWuID); to analyse perceptions,
attitudes, ownership, and experience of HIV self-testing;
and to analyse the social effects of HIV self-testing at
the individual, collective and health system level.
Qualitative surveys will be conducted (individual in-
depth interviews and focus group discussions) in the
three countries with (i) key actors in testing programmes
targeting key populations (FSW, MSM, PWuID); (ii)
members of the three key population communities and
(iii) HIV self-test users recruited either by peer educa-
tors or through the Coupons survey. The different sub-
studies are described in Table 3 and will be conducted
sequentially. They will be complemented by document
review (press articles, HIVST promotional documents).
Index testing WP
The specific objectives of this WP are to describe how
HIV care services and healthcare professionals integrate
HIV self-testing for sexual partners of PLHIV; to study
how PLHIV negotiate issues around the HIV self-testing
proposal to their partner(s); to analyse perceptions, uses
and modalities of use of HIV self-tests by partners; and
to identify individual, marital and social impacts.
This WP will use anthropological methods, consisting
primarily of ethnographic observations and individual
in-depth interviews.
The study survey will be conducted in all three ATLA
S countries, with an ethnographic study in three HIV
clinics (one per country) where HIVST is offered as part
of the ATLAS programme’s dispensing activities (2.5
months in each clinic). It will include both (i) observa-
tions of consultations, medical staff and any other
Table 1 Work package and secondary objectives















HIVST users Dispensing sites,
Dispensing agents
–
SO1 Identify the social, cultural and organisational factors
facilitating and limiting the primary and secondary distribution
of HIVST kits and their use by the different actors involved.
✓ ✓
SO2 Define the socio-behavioural profile and HIV testing
history of HIVST users and their care pathway in the event
of a reactive test.
✓ ✓
SO3 Analyse the positive and negative social and health
consequences of the introduction of HIVST for individuals,
communities and the health system.
✓ ✓ ✓
SO4 Estimate the incremental costs of dispensing HIVST
kits per dispensing channel.
✓
SO5 Model the epidemiological impacts of the ATLAS
programme and different scale-up scenarios on epidemic
dynamics.
✓ ✓
SO6 Estimate the cost-effectiveness and the medium-
and long-term budgetary impact of different scaling strategies.
✓ ✓
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activities organised in connection with the distribution
of HIVST; and (ii) in-depth individual interviews with
PLHIV followed in the service who were offered an
HIVST to distribute to their partners, PLHIV partners
who have accepted or refused HIVST and health staff.
At the project end, over 2 weeks, some health workers
and patients interviewed during the ethnographic studies
will be re-interviewed to evaluate HIVST appropriation
by the different actors and the expected and unexpected
repercussions and difficulties after several months of
implementation.
The content of the interviews and observations will be
subject to thematic analysis using the online content
analysis software Dedoose. Data analysis will be based
on a Grounded Theory approach [48], i.e., a theory de-
veloped by induction from a corpus of data. The analyt-
ical framework of this WP will be based on a
sociological approach to gender [49].
Coupons survey WP
Specific objectives of the coupons survey are to docu-
ment the socio-behavioural profile and screening history
of HIV self-tests users; to identify the care trajectories of
these HIV self-tests users following a reactive or indeter-
minate self-test; and to provide an empirical estimate of
some parameters used by the WP Modelling. The survey
was designed to enable data collection from HIVST end-
users based on anonymity and voluntary participation
through the establishment of an anonymous and free
telephone platform in the three countries.
To be eligible for the study, participants must be of
legal age to perform an HIV test by him/herself (i.e., 16+
years old in Côte d’Ivoire, 18+ in Mali and 15+ in
Senegal) and have performed an HIVST.
The survey will be organised in collection waves with
two phases each. A pilot study will be conducted before
the implementation of the full survey.
Survey phase 1
During phase 1 of each wave, all HIVST kits distributed
in the country through ATLAS, regardless of delivery
channel, will contain an invitation to participate in the
study (the “coupons”). Similarly, anyone calling the na-
tional HIV hotline during this period and reporting hav-
ing performed an HIVST will be invited to participate in
the coupons survey by calling the dedicated survey free
phone number.
All HIVST kits distributed under the ATLAS
programme will also be marked using a coloured sticker
with a numbered code to identify the delivery channel
and the technical implementation partner. During the
telephone interview, the participant will be asked for the
colour and number of the sticker to be able to associate
each questionnaire with a dispensing channel.
When a person calls one of the study’s toll-free num-
bers, they will first be presented with the study and then
asked to state orally whether they consent to participate
(verbal consent, time-stamped). If consent is given, a 15-
min questionnaire will be administered. This question-
naire will cover the participant’s socio-demographic
characteristics, his or her HIV testing history, sexual
practices, knowledge of HIVST, ease of use of the HIVS
T kit and the result of his/her self-test.
Survey phase 2
Phase 1 participants who reported a reactive or indeter-
minate HIVST result and who agreed to be contacted
again will be called back 3months after completion of
the phase 1 questionnaire for the phase 2 questionnaire.
This second questionnaire aims to document the partici-
pant’s care trajectory and, in particular, whether a con-
firmatory test has been performed and, if so, whether
the person linked to HIV care and initiated antiretroviral
treatment.
Cost study WP
Because HIVST is being added onto existing HIV testing
programmes, the specific objectives of the cost WP are
to estimate the incremental costs of providing HIVST;
to compare the costs of HIVST to other HIV testing ap-
proaches; to model medium- and long-term scale-up
costs; and to compare costs to expected epidemiological
impacts (Modelling WP) to estimate the cost-
effectiveness of these scale-up scenarios.
We will conduct an incremental HIVST cost analysis
to capture economic costs (i.e., all resources used, in-
cluding donated goods and services) of the intervention.
We will also conduct a full economic cost analysis of a
sample of conventional HIV testing sites where HIVST
is being introduced. The analysis will follow the recom-
mendations of the Global Health Cost Consortium,
which sets standards for health costing studies [50].
Data collection includes (i) a top-down cost approach
with programmatic cost data; (ii) a bottom-up cost ap-
proach with a representative sample of HIV self-tests
distribution sites; and (iii) a time-motion study with a
sample of dispensing agents (Table 4).
The analysis will take a provider’s perspective. We will
estimate programme development, start-up, and imple-
mentation costs, capturing both capital costs (infrastruc-
ture, equipment, etc.) and recurrent costs (salaries, HIVS
T kits, etc.). The cost analysis will differentiate between
the start-up phase (all costs incurred before the first
HIV kits are distributed) and the “implementation”
phase (one-year observation period following the begin-
ning of HIVST kit distribution). For each country and
delivery channel, the main output will be the total
programme costs and average cost per HIVST kit
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delivered (HIVST cost), and per person tested for HIV/
per HIV-positive case identified (HTS cost). Based on
the observed costs of early implementation, we will
model costs at scale and consider the budgetary impact
of alternative HIV testing programme models.
Modelling WP
The impact of HIVST is not limited to the diagnosis of
PLHIV. By identifying more PLHIV unaware of their status
(and identifying them more rapidly), there is potential to re-
duce the average length of time that a person is at risk of
transmitting the virus. In this way, HIVST can reduce the
morbidity and mortality of newly diagnosed infected people
if they are promptly linked to care, as well as reducing on-
ward transmission if they achieve viral load suppression [51].
Such medium- and long-term effects cannot be easily
empirically measured, and mathematical models of HIV
transmission dynamics offer a robust alternative. For ex-
ample, different scenarios (with or without the introduc-
tion of HIVST, for example) can be compared to
estimate incremental gains in new infections prevented,
life-years gained, and deaths avoided. Diverse scenarios
can be explored, and sensitivity analyses conducted. Epi-
demic modelling is a valuable tool for answering these
types of questions and for providing insights into the
possible impacts of different health policies related to
HIVST. This tool is also essential for a better under-
standing of the current epidemic dynamics and im-
proved focus of activities to be performed.
The specific objectives of the Modelling WP are to
identify population groups most likely to acquire and
transmit HIV and to identify their testing and diagnostic
delays; to estimate the population impact of the intro-
duction of HIVST in the three ATLAS countries, at the
scale achieved by the ATLAS programme and under
possible scale-up scenarios; and to estimate the cost-
effectiveness of these scale-up scenarios and conduct
sensitivity analysis.
Several existing dynamic models of HIV transmission
that have already developed and calibrated to the HIV
epidemic in West Africa will be leveraged [12, 13, 52,
53]. These models will be adapted to the idiosyncrasies
of HIVST [53], parameterised, and calibrated to detailed
epidemiological and intervention data collected as part
of the ATLAS programme.
Briefly, the model will represent an open (15–59 years)
and growing population stratified by four age groups (15–
19, 20–24, 25–49, and 50–59 years). Also, different risk
groups and levels of sexual activity will be considered: low-
and high-risk women, low- and high-risk men, sex workers,
clients of sex workers, men who have sex with men and
women, and men who have sex exclusively with men. The
model considers the age of sexual debut, as well as the mi-
gration and mortality due to HIV or other causes.
The model represents natural HIV progression from
the initial/acute highly infectious phase to the chronic
phase. The model also describes the treatment and care
continuum: testing, management, and initiation of anti-
retroviral therapy. This description of the continuum of
care helps to determine the three stages of the UNAIDS
90–90-90 target in each subpopulation group (Fig. 2).
Sexually active individuals at risk may acquire HIV in-
fection at a rate that depends on their annual number of
sexual partners and sexual acts, the type of sexual part-
ners and sexual acts (vaginal or anal), the prevalence of
HIV among their sexual partners and their stage of in-
fection, and their initiation of treatment, the type of sex,
and the rate of condom use.
Parameterisation and calibration
The model will have to be parameterised and calibrated
for the three ATLAS countries. The model parameters
Table 4 Cost study WP
Top-down approach Analysis of programmatic costs (top-down cost) based on Solthis and implementing partners’ financial and activity reports.
This analysis will include shared overhead costs of the programme.
Bottom-up cost
approach
Based on a sample of sites where both HTS and HIVST distribution are ongoing. Dispensing sites will be randomly sampled
considering the dispensing strategies implemented in each site (fixed and mobile strategies), the geography of the site
(country, region). About 60 sites will be investigated (~ 30 in Côte d’Ivoire, ~ 15 in Mali and ~ 15 in Senegal). The data
collected will cover both the costs of dispensing HIV kits and other HIV testing activities conducted on-site. It will include
specific costs of the ATLAS programme, as well as costs covered by other donors (e.g., Global Fund, Pepfar) and economic
costs not reported in financial reports (e.g., donations of goods and services), as well as allocation factors for the disaggrega-
tion of costs by delivery models. The collection will be based on the various reporting documents produced by the structure
(financial reports, activity reports, etc.) and on individual interviews conducted with the technical and financial managers of
the structure. The interview document with the person in charge on-site will serve as a working basis for the development
of a data collection tool by research assistants and will be piloted for adaptation to the different sites in each country.
Time-motion study To complement the bottom-up approach, a time-motion study will be conducted to disaggregate field-based personnel
time between HIVST-related activities and other activities to use this information as an allocation factor of personnel costs
between HIVST delivery models. The number of providers to be surveyed will be determined based on the preliminary re-
sults of the bottom-up approach. Specifically, for each survey day at a given site, the research team will list the providers ac-
tive on that day and verbally ask each provider if they are willing to participate. Among those who have indicated a
willingness to participate in the study, a random draw will be held to select the person(s) to be followed on that day. Writ-
ten informed consent will be obtained from study participants.
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come from four different areas: (i) demographic (age
structure, mortality, etc.); (ii) biological (probability of
transmission, treatment effectiveness, etc.); (iii) behav-
ioural (number of sexual partners, condom use, etc.) and
(iv) national response (testing, antiretroviral coverage,
etc.).
The model will then be calibrated within a Bayesian
framework to identify the model parameters that best re-
produce HIV epidemic trends in the different subgroups,
as well as the evolution of the coverage of interventions
(e.g., condom use and treatment uptake).
Simulations and analyses
Once the three models have been parameterised and cal-
ibrated, they will be used to reproduce different hypo-
thetical or observed scenarios:
– The ATLAS programme as implemented
– The screening programme without the
implementation of ATLAS
– Various ATLAS scaling scenarios (determined with
the economic component)
Last, we compare costs (Cost Study WP) with ex-
pected epidemiological impacts to estimate the cost-
effectiveness of these scaling scenarios.
Participants and public involvement
At each stage of the research implementation, communi-
ties were involved in the research programme. Stake-
holders and local Civil Society Organisations (CSO)
participated in programme development workshops
which helped to develop the research questions.
Throughout the project, communities, stakeholders
and local CSO will be consulted at least once a year
through the consortium meetings that bring together all
to discuss the progress, results and interpretation of the
research. A representative of the Ministry of Health of
each country is also associated with the research team
which meets annually.
Discussion
No HIVST kits will be distributed as part of the research
activities of this protocol, as all HIVST kits under the
ATLAS programme are provided as part of routine
Fig. 2 Proposed flowchart describing flows between the main compartments describing testing behaviors and modalities, HIV acquisition,
diagnosis, linkage to care, and ART initiation and discontinuation
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testing activities validated by the national AIDS
programme of the country involved.
There should be no risk or consequence whatsoever
associated with the refusal to participate in one, several
or all of the proposed studies. In no way will participa-
tion or non-participation in any of the studies conducted
impact (positively or negatively) access to HIVST kits.
Participation in research will be voluntary.
There is no major individual health risk to participate
in these studies. The primary risk is social; if one re-
spondent sees another person participating in this study,
he or she may make assumptions about his or her sero-
logical status and/or practices, which may be illegal (sex
work, sex between men, drug use, etc.) and reveal them
to the community. Measures are put in place to avoid
this: interviews will be conducted in confidential places,
data will be coded and kept in safe places, and records
will be destroyed at the end of the project.
A website dedicated to the ATLAS programme
(https://atlas.solthis.org) allows participants in the differ-
ent studies to access the research protocol, the different
information records of each study, and the results when
they are available.
ATLAS is the first comprehensive study on HIV self-
testing in West Africa. The ATLAS programme focuses
particularly on the secondary distribution of HIVST.
This study will also be the first to analyse the use of HIV
self-testing among people who use injectable drugs in
Africa. This is a multidisciplinary study that employs
both qualitative and quantitative methods.
ATLAS research is an innovative approach to docu-
ment HIV self-testing use, interfering as less as possible
with routine activities and without actively tracking
HIVST users to preserve confidentiality and anonymity.
Ethical approvals
The ATLAS protocol version 2.1 has been reviewed and
approved by the following ethical committees:
 Comité National d’Ethique des Sciences de la vie et
de la santé de Côte d’Ivoire (ref: 049–19/MSHP/
CNESVS-kp, 28th May 2019),
 Comité d’Éthique de la Faculté de Médecine et de
Pharmacie de l’université de Bamako Mali (ref:
2019/88/CE/FMPOS, 14th August 2019),
 Comité National d’Ethique pour la Recherche en
Santé du Sénégal (ref: SEN19/32, 26th July 2019),
 Ethical Research Committee of the World Health
Organisation (ERC 0003181, 7th August 2019),
 LSTHM IRB (ref: 17141, 25th April 2019).
Consent procedures
Our consent procedures include (i) signed consent form
for face-to-face in-depth interviews, focus groups and
time and motion study; (ii) specific consent obtained for
audio recording interviews; (iii) authorisation of the
manager of the dispensing sites and consent of the care-
givers for the ethnographic studies and bottom-up cost;
and (iv) anonymous time-stamped oral verbal consent
for phone surveys.
Data monitoring plan
A data monitoring plan (DMP) has been developed and
specifies the list of data collected in the framework of
ATLAS research, their documentation and metadata,
ethical and legal aspects, data storage and backup, intel-
lectual property rights, a reminder of ethical aspects,
rules for sharing, disseminating and reusing data, and
rules for archiving and data preservation. This data man-
agement plan is publicly available on the Opidor plat-
form: https://dmp.opidor.fr/plans/3354/export.pdf and is
compliant with the European General Data Protection
Regulation.
Supplementary Information




ARV: Antiretroviral; CSO: Civil Society Organisations; DMP: Data Monitoring
Plan; FSW: Female Sex Workers; HIVST: HIV self-testing; HTS: HIV testing
services; MSM: Men who have Sex with Men; PLHIV: People Living with HIV;
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